Results 101 to 110 of about 2,454,151 (187)

Neuromyelitis Optica Spectrum Disorders: Diagnosis and Treatment

, 2011
The last decade has witnessed rapid developments in the clinical understanding and scientific foundation of neuromyelitis optica (NMO).curriculum_fellow; IC-E4cii1-relationships-between-optic-neuritis-and-multiple-sclerosis; IC-E4cii3-classification-and ...
Dean M. Wingerchuk, MD, MSc, FRCP(C)
core  

Neuromyelitis optica spectrum disorder mimicking multiple sclerosis

, 2017
Background MS is a demyelinating CNS disease and has distinct clinical and radiological features. Neuromyelitis optica spectrum disorder (NMOSD) is an antibody related auto-immune disease known for invalidating episodes of myelitis and optic neuritis ...
Wattjes, Mike P., van Oosten, Bob W., van Rooij, Lucas C., de Jong, Brigit A.   +3 more
core   +1 more source

Proteomic profile of CSF obtained at the time of diagnosis determines amyotrophic lateral sclerosis progression and survival: CXCL7 levels in disease prognosis and survival

Brain Pathology, Volume 36, Issue 5, September 2026.
Untargeted multiomic profiling of cerebrospinal fluid reveals that proteomic, but not lipidomic, signatures robustly distinguish ALS patients from controls and stratify individuals by survival, highlighting marked molecular differences between short survival and long survival disease.
Sergio Roca‐Pereira, Yaiza López‐Sampere, Pol Mengod‐Soler, Mario Peña‐Fonteboa, Carla Marco, Alejandro Caravaca‐Puchades, Raúl Domínguez, Juan Francisco Vázquez‐Costa, Enrique Santamaría, Joaquín Fernández‐Irigoyen, María J. Colomina, Isabel León Moreno, Antonio Martínez Yélamos, Sergio Martínez Yélamos, Gabriel Santpere, Elia Obis, Manuel Portero‐Otín, Gerard Piñol‐Ripoll, Mónica Povedano, Pol Andrés‐Benito   +19 more
wiley   +1 more source

Management of neuromyelitis optica spectrum disorder at the Escuela Hospital, Honduras [PDF]

Neuromyelitis optica spectrum disorder is an autoimmune-based nosological entity with inflammatory characteristics that affects the central nervous system: optic nerves, spinal cord and brainstem.
Auza-Santivañez , Jhossmar Cristians, Carías, Pablo, Carías , Alejandro, Bautista-Vanegas, Freddy Ednildon, Escalante , Dulce, Lagos, Gabriel Isaias, Estrada Pastrana , Harlis, Villca-Villca , Dilma   +7 more
core   +1 more source

Integrated Engineering of CAR‐T Cells for Solid Tumours

Cell Proliferation, Volume 59, Issue 9, September 2026.
Solid tumours pose multifactorial barriers including antigen heterogeneity, immunosuppressive microenvironment, and poor T‐cell trafficking, limiting CAR‐T efficacy compared to hematologic malignancies. Integrated engineering strategies are essential, combining logic‐gated receptors for precision, metabolic‐epigenetic reprogramming for resilience, and ...
Chao Yang, Tan Li, Ping He, Zhijie Zhao, Shenglong Li, Liming Wang   +5 more
wiley   +1 more source

Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder

, 2018
BACKGROUND: It is unknown if vaccines cause non-specific immune activation in patients with neuromyelitis optica spectrum disorder and no consensus on the use of vaccines exists for this population.
Velez, D.L., Paul, F., Becker, D., Mealy, M.A., Lawrence J. Cook, Florence Pache, Diego L. Velez, Jimenez Arango, J.A., Friedemann Paul, Borisow, N., Pache, F., Nadja Borisow, Levy, M., Jorge A. Jimenez Arango, Daniel Becker, Michael Levy, Maureen A. Mealy, Cook, L.J.   +17 more
core   +1 more source

Physiologically Based Pharmacokinetic Modeling to Predict Human Starting Dose and Pharmacokinetics for Rocbrutinib

Clinical and Translational Science, Volume 19, Issue 9, September 2026.
ABSTRACT Rocbrutinib is a fourth‐generation Bruton's tyrosine kinase (BTK) inhibitor that covalently binds wild‐type BTK and non‐covalently engages the C481S mutant. Its pharmacokinetic (PK) characteristics in healthy Chinese subjects remain unclear. This study aimed to support maximum recommended starting dose (MRSD) selection and predict exposure of ...
Lu Wang, Dandan Yang, Rong Shao, Jinliang Chen, Xiaodan Wang, Zheng Wang, Bo Jiang   +6 more
wiley   +1 more source

Practical Guidance on Initiating and Switching Targeted Immunotherapies in Generalised Myasthenia Gravis: A German–Austrian Expert Opinion Paper

European Journal of Neurology, Volume 33, Issue 9, September 2026.
ABSTRACT Background The therapeutic landscape of generalised myasthenia gravis (gMG) has evolved substantially with the approval of targeted immunotherapies, including complement C5 inhibitors (C5‐I) and neonatal Fc receptor inhibitors (FcRn‐I). While pivotal trials have demonstrated marked efficacy in defined subgroups, real‐world experience reveals ...
Andreas Meisel, Adela Della Marina, Paolo Doksani, Tim Hagenacker, Christoph Kleinschnitz, Heidrun H. Krämer, Jan D. Lünemann, Sven G. Meuth, Tobias Ruck, Ulrike Schara‐Schmidt, Christiane Schneider‐Gold, Benedikt Schoser, Michael Schroeter, Charlotte Schubert, Jörn Peter Sieb, Fritz Zimprich, Jana Zschüntzsch, Sarah Hoffmann   +17 more
wiley   +1 more source

Development of Neuromyelitis Optica Spectrum Disorder and Spinal Arachnoid Cysts in a Patient With Intractable Epilepsy

, 2018
Neuromyelitis optica is an inflammatory, demyelinating disease of the central nervous system that is characterized by severe relapsing attacks of optic neuritis and transverse myelitis.
Yin Liu, Michael Olek
core   +1 more source

BAFF and APRIL Receptors in B Cell Immunity and Autoimmunity

Immunological Reviews, Volume 342, Issue 1, September 2026.
ABSTRACT BAFF and APRIL are TNF superfamily proteins that bind to BAFFR, TACI and BCMA, members of the TNF receptor superfamily. These proteins have both unique and overlapping roles in B cell development and survival and are major therapeutic targets for antibody‐ and B‐cell‐driven pathologies.
Daisy H. Luff, Edina Schweighoffer, Victor L. J. Tybulewicz   +2 more
wiley   +1 more source